Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Allogeneic Stem Cell Transplantation for High-Risk Multiple Myeloma

Rohan Vuppala, Charles Weeks, Mark Dalgetty, Danielle Bradshaw, Locke Johnson Bryan, Amany R. Keruakous, Anand Jillella, Vamsi K. Kota, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 7401.

https://doi.org/10.1182/blood-2024-211898

Published: 2024

Journal Articles

Incidence of Engraftment Syndrome with and without Budesonide Prophylaxis in Patient with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Stephanie Daniels, Lucy Gloe, Vamsi K. Kota, Alexandria Rakestraw, Amber Clemmons

Blood (2024) 144 (Supplement 1): 7116.

https://doi.org/10.1182/blood-2024-210832

Published: 2024

Journal Articles

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Blood (2024) 144 (Supplement 1): 5174.

https://doi.org/10.1182/blood-2024-198914

Published: 2024

Journal Articles

Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes

Marisol Miranda, Kellen Cristine Tjioe, Muhannad Sharara, Maloney Mckenzie, Amany R. Keruakous, Locke Johnson Bryan, Anand Jillella, Vamsi K. Kota, Avirup Guha, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 3160.

https://doi.org/10.1182/blood-2024-209114

Published: 2024

Journal Articles

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Blood (2024) 144 (Supplement 1): 221.

https://doi.org/10.1182/blood-2024-201595

Published: 2024

Journal Articles

Financial Toxicity of FDA-Approved Hematologic Malignancy Drugs: An Epidemiological Analysis of Cost

Charles Weeks, Mahran Shoukier, Mark Dalgetty, Rohan Vuppala, Shreya Desai, Abigayle B Simon, Vamsi K. Kota, Locke Johnson Bryan, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 7578.

https://doi.org/10.1182/blood-2024-206129

Published: 2024

Journal Articles

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood (2024) 144 (Supplement 1): 4184.

https://doi.org/10.1182/blood-2024-205812

Published: 2024

Journal Articles

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Yannis K. Valtis, David Nemirovsky, Sean M. Devlin, Gregory W Roloff, Ibrahim Aldoss, Nikeshan Jeyakumar, Katharine Miller, Amy Zhang, Katherine C. Sutherland, Anjali S. Advani, Marlise R. Luskin, Evan C. Chen, Omer Jamy, Michael R. Grunwald, Ibrahim Muhsen, Noam E. Kopmar, Bhagirathbhai Dholaria, Simone E. Dekker, Jessica T. Leonard, George Yaghmour, Stephanie B. Tsai, Wendy Stock, Jozal Moore, Kristen M. O'Dwyer, Aaron C. Logan, Matthew P Connor, Noelle Frey, Evandro Bezerra, Sumithira Vasu, Kaitlyn C Dykes, Minoo Battiwalla, Chenyu Lin, Matthew Ulrickson, Ran Reshef, Ryan D. Cassaday, Laquisha C. Hill, Catherine J. Lee, Vamsi K. Kota, Jacob Boccucci, Joshua Sasine, Akil Merchant, Vinod Pullarkat, Amelia Langston, Talal Hilal, Rawan Faramand, Melhem M. Solh, Tamer Othman, Timothy E O'Connor, Navneet Majhail, Shabaz Malik, Luke Mountjoy, Rasmus T. Hoeg, Caspian H. Oliai, Vishal Gupta, Divya Koura, Muthu V. Kumaran, Marc Schwartz, Veronika Bachanova, Sean I. Tracy, Maria Odstrcil Bobillo, Abdullah Ladha, Clayton Jackson, Vivian Irrizary Gatell, Olalekan O. Oluwole, Michael Daunov, John Mathews, Paul Shaughnessy, Bijal D Shah, Lori Muffly, Jae H. Park

Blood (2024) 144 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2024-201610

Published: 2024

Journal Articles

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Elias Jabbour, David Wei, Hongbo Yang, Kejal Jadhav, Wei Song, Yajin Zhao, Anran Shao, Samantha Tomicki, Daisy Yang, Andrea Damon, Islam Sadek, Vamsi K. Kota

Blood (2024) 144 (Supplement 1): 2434.

https://doi.org/10.1182/blood-2024-201831

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Journal Articles

Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Ibrahim Muhsen, Anjali S. Advani, Gregory W Roloff, Nikeshan Jeyakumar, Katharine Miller, Amy Zhang, Katherine C. Sutherland, Michael R. Grunwald, Vamsi K. Kota, Jacob Boccucci, Matthew Ulrickson, Joshua Sasine, Ibrahim Aldoss, Tamer Othman, Sumithira Vasu, Ran Reshef, Marlise R. Luskin, Evan C. Chen, Chenyu Lin, Amelia Langston, Ryan D. Cassaday, Noam E. Kopmar, Stephanie B. Tsai, Timothy E O'Connor, Talal Hilal, Rawan Faramand, Jae H. Park, Yannis K. Valtis, Melhem M. Solh, Evandro Bezerra, Jessica T. Leonard, Simone E. Dekker, Navneet Majhail, Minoo Battiwalla, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Luke Mountjoy, Rasmus T. Hoeg, Caspian H. Oliai, Vishal Gupta, Divya Koura, Kaitlyn C Dykes, Aaron C. Logan, Muthu V. Kumaran, Wendy Stock, Marc Schwartz, Veronika Bachanova, Sean Tracy, Kristen M. O'Dwyer, Jozal Moore, Catherine J. Lee, Maria Silvina Odstrcil Bobillo, Noelle Frey, Matthew P Connor, Omer Jamy, Michael Daunov, Abdullah Ladha, George Yaghmour, Clayton Jackson, Vivian Irrizary Gatell, Olalekan O. Oluwole, Bhagirathbhai Dholaria, Vinod Pullarkat, Akil Merchant, Bijal D Shah, Lori Muffly, LaQuisa Hill

Blood (2024) 144 (Supplement 1): 523.

https://doi.org/10.1182/blood-2024-210682

Published: 2024

Journal Articles

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav

Blood (2023) 142 (Supplement 1): 5190.

https://doi.org/10.1182/blood-2023-180789

Published: 2023

Journal Articles

Intensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia

Alexandra E. Rojek, Benjamin J. McCormick, Joanna Cwykiel, Oluwatobi Odetola, Yasmin Abaza, Rohan Achar, Rory M. Shallis, Danielle Bradshaw, Meaghan Standridge, Vamsi K. Kota, Talha Badar, Anand Ashwin Patel

Blood (2023) 142 (Supplement 1): 2889.

https://doi.org/10.1182/blood-2023-177758

Published: 2023

Journal Articles

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Vamsi K. Kota, David Wei, Daisy Yang, Hela Romdhani, Dominick Latremouille-Viau, Annie Guérin, Kejal Jadhav

Blood (2023) 142 (Supplement 1): 5098.

https://doi.org/10.1182/blood-2023-180772

Published: 2023

Journal Articles

Therapy Related Multiple Myeloma: A Distinct Entity

Meaghan Standridge, Shreya Desai, Sujith Abbagoni, Sabrina Matosz, Danielle Bradshaw, Mohammad Mian, Mohommed Syam, Vamsi K. Kota, Jorge Cortes, Amany R. Keruakous, Ayushi Chauhan, Locke Johnson Bryan, Anand Jillella

Blood (2023) 142 (Supplement 1): 6657.

https://doi.org/10.1182/blood-2023-190298

Published: 2023

Journal Articles

Outcomes of Regimented Weight Monitoring on Morbidity and Mortality during AML Induction

Anvay Shah, Nabil Ghani, Danielle Bradshaw, Anand Jillella, Vamsi K. Kota, Jorge Cortes, Mark Dalgetty, Zachery Branham, Sandeep Yerraguntla, Locke Johnson Bryan, Amany R. Keruakous, Ayushi Chauhan

Blood (2023) 142 (Supplement 1): 5875.

https://doi.org/10.1182/blood-2023-190979

Published: 2023

Journal Articles

Outcomes in Acute Lymphoid Leukemia Patients with Incomplete Hyper-CVAD Cycles

Sabrina Matosz, Meaghan Standridge, Danielle Bradshaw, Amany R. Keruakous, Jorge Cortes, Mohammad Mian, Locke Johnson Bryan, Anand Jillella, Ayushi Chauhan, Vamsi K. Kota

Blood (2023) 142 (Supplement 1): 5887.

https://doi.org/10.1182/blood-2023-190334

Published: 2023

Journal Articles

The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Ibrahim Aldoss, Gregory W Roloff, Anjali S. Advani, Noam E. Kopmar, Chenyu Lin, Simone E. Dekker, Vishal K Gupta, Nikeshan Jeyakumar, Timothy E O'Connor, Amy Zhang, Katharine Miller, Kaitlyn C Dykes, Mohamed Ahmed, Hector Zambrano, Danielle Bradshaw, Santiago Mercadal, Marc Schwartz, Sean Tracy, Bhagirathbhai Dholaria, Michal Kubiak, Akash Mukherjee, Navneet Majhail, Minoo Battiwalla, Luke Mountjoy, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Aaron C. Logan, Abdullah Ladha, George Yaghmour, Maryann Stefan, Caitlin Guzowski, Rasmus T. Hoeg, Talal Hilal, Jozal Moore, Kristen M. O'Dwyer, Stephanie B. Tsai, Joshua Sasine, Melhem M. Solh, Catherine J. Lee, Vamsi K. Kota, Divya Koura, Muthu Veeraputhiran, Betsy Blunk, Jessica T. Leonard, Caspian H. Oliai, Veronika Bachanova, Wendy Stock, Ahmed Galal, Vinod Pullarkat, Ryan D Cassaday, Bijal D. Shah, Rawan Faramand, Lori S. Muffly

Blood (2023) 142 (Supplement 1): 4877.

https://doi.org/10.1182/blood-2023-182404

Published: 2023

Journal Articles

Prephase Cyclophosphamide: An Advantageous Bridge to Definitive Therapy

Meaghan Standridge, Shreya Desai, Sandeep Yerraguntla, Danielle Bradshaw, Mohammad Mian, Vamsi K. Kota, Anand Jillella, Jorge Cortes, Ayushi Chauhan, Amany R. Keruakous, Locke Johnson Bryan

Blood (2023) 142 (Supplement 1): 6316.

https://doi.org/10.1182/blood-2023-190805

Published: 2023

Journal Articles

Are Pivotal CART Trials Representative of Population at Risk?

Anvay Shah, Vamsi K. Kota, Mycal Casey, Lorriane Odhiambo, Vishrut Shah, KM Islam, Anand Jillella, Locke Johnson Bryan, Amany R. Keruakous, Ayushi Chauhan, Jorge Cortes

Blood (2023) 142 (Supplement 1): 5884.

https://doi.org/10.1182/blood-2023-191122

Published: 2023

NARROW

Allogeneic Stem Cell Transplantation for High-Risk Multiple Myeloma

Incidence of Engraftment Syndrome with and without Budesonide Prophylaxis in Patient with Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium

Clinical Assessment of Cumulative Stress Via Allostatic Load in Chronic Myeloid Leukemia Patients: Implications for Treatment Outcomes

Gilteritinib Results in Higher Remission and Transplant Rates Than Midostaurin but Does Not Increase the Post-Induction Mutational MRD Negative Rate: Results of the Phase 2 Randomized Precog 0905 Study in Newly Diagnosed FLT3 Mutated AML

Financial Toxicity of FDA-Approved Hematologic Malignancy Drugs: An Epidemiological Analysis of Cost

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Treatment Patterns and Modifications of Tyrosine Kinase Inhibitors (TKI) Therapy in Early Lines in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Real-World Analysis from a Large Commercial Claims Database in the United States (US)

Intensive Induction Chemotherapy with or without Gemtuzumab Ozogamicin Among Patients with Core-Binding Factor Acute Myeloid Leukemia

Incremental Healthcare Resource Utilization and Costs Associated with Non-Optimal Treatment in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Tyrosine Kinase Inhibitors (TKI) in Early Lines of Therapy in the United States (US)

Therapy Related Multiple Myeloma: A Distinct Entity

Outcomes of Regimented Weight Monitoring on Morbidity and Mortality during AML Induction

Outcomes in Acute Lymphoid Leukemia Patients with Incomplete Hyper-CVAD Cycles

The Impact of Inotuzumab Ozogamicin (InO) Treatment on Brexucabtagene Autoleucel (Brexu-cel) Outcomes in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Prephase Cyclophosphamide: An Advantageous Bridge to Definitive Therapy

Are Pivotal CART Trials Representative of Population at Risk?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only